CMV Retinitis: Protecting Your Vision
Understanding CMV Retinitis
CMV retinitis is an infection of the retina caused by cytomegalovirus, a common virus in the herpesvirus family. Most healthy people carry CMV without any problems because their immune system keeps it in check. When the immune system is severely weakened, the virus can reactivate and attack the retina.
The infection causes progressive damage to the retinal tissue. The virus infects all layers of the retina as well as the retinal pigment epithelium (RPE), a supportive layer beneath the retina. Infected cells become enlarged and develop abnormal viral material inside them. Without treatment, the area of damaged retina spreads to surrounding healthy tissue.
CMV retinitis is characterized by spreading areas of retinal death, bleeding, and inflammation. Retina specialists often describe the appearance as resembling a 'pizza pie.' This is because of the combination of white, necrotic retinal tissue mixed with areas of reddish hemorrhage. As the infection progresses, it destroys retinal cells that are essential for vision.
The virus establishes a dormant state in certain immune cells called myeloid progenitor cells. Even after treatment, the virus can reactivate if the immune system weakens again. Without ongoing immune recovery or maintenance therapy, the infection can return.
CMV retinitis develops in people whose T-cells, a critical part of the immune system, are not working properly. This can happen when a person has not built a strong immune response to CMV. It can also happen when a previously effective immune response has been weakened by disease or medication. T-cells are essential for keeping CMV dormant. When their numbers or function drop severely, the virus can attack the retina.
Who Is Affected and Risk Factors
The most well-known risk group for CMV retinitis is people living with HIV, especially those with advanced AIDS. Before widespread use of highly active antiretroviral therapy (HAART), about 30 percent of people with AIDS developed CMV retinitis (AAO EyeWiki). The disease typically occurs when CD4+ T-cell counts fall below 50 cells per microliter. It rarely develops when counts are above 100 cells per microliter (Review of Ophthalmology).
People with HIV who are at the highest risk include those not receiving antiretroviral treatment and those whose treatment has failed. Additional risk factors include very high HIV viral loads and a history of other opportunistic infections (Review of Ophthalmology).
People who have received solid organ transplants are also at risk for CMV retinitis. These patients take immunosuppressive medications to prevent organ rejection, which weakens their immune defenses. The risk is greatest in patients who have not been previously exposed to CMV but receive an organ from a donor who carries the virus.
CMV retinitis can also affect other people with severely weakened immune systems. These groups include:
- Patients undergoing chemotherapy for cancer
- People taking strong immunosuppressive medications for autoimmune conditions
- Newborns with congenital immune deficiencies
- Elderly individuals with declining immune function
Recent medical reports have also shown that strong local immunosuppression in the eye itself can be a risk factor. This may occur even without widespread immune suppression throughout the body.
Signs and Symptoms
In the earliest stages, CMV retinitis may cause no symptoms at all. Studies have found that about 32 percent of patients had no symptoms at diagnosis (AAO EyeWiki). When early symptoms do appear, the most common complaint is new floaters. These are small spots or cobweb-like shapes drifting across the field of vision.
As the infection advances, patients may notice a shadow or dark area in their side vision. This shadow may gradually expand as more of the retina is damaged. Blurred vision occurs in about 48 percent of cases, and floaters in about 18 percent (AAO EyeWiki).
Other symptoms that may develop include flashes of light and a veil or curtain effect across part of the visual field. If the infection reaches the macula, the central part of the retina responsible for sharp vision, significant central vision loss can occur. This vision loss may be long-lasting.
Certain vision changes require immediate medical attention. If you have a weakened immune system and experience a sudden increase in floaters, flashes of light, a curtain or shadow over your vision, or sudden vision loss in one eye, see a retina specialist or go to the emergency room immediately. These symptoms may indicate rapidly progressing CMV retinitis or a retinal detachment.
Diagnosis and Testing
CMV retinitis is most often diagnosed through a thorough dilated eye examination. A retina specialist will use special lenses and instruments to examine the retina in detail. The characteristic appearance of CMV retinitis, with areas of white, dead retinal tissue mixed with hemorrhage, is often enough to make the diagnosis. The location and extent of the infection are carefully documented to guide treatment decisions.
Because many patients with CMV retinitis have no symptoms in the early stages, regular screening is essential for people at high risk. Patients with CD4 counts below 50 cells per microliter should have follow-up eye examinations at least every three months (Review of Ophthalmology). Early detection allows treatment to begin before significant vision loss occurs.
In some cases, a retina specialist may order additional tests to confirm the diagnosis or assess the extent of damage. These may include optical coherence tomography (OCT), which creates detailed cross-sectional images of the retina. Fundus photography captures high-resolution pictures of the retina for ongoing monitoring. In uncertain cases, a small sample of fluid from inside the eye may be tested for CMV DNA using polymerase chain reaction (PCR).
Treatment Options
The primary treatment for CMV retinitis involves antiviral medications that fight the virus throughout the body. Several FDA-approved options exist, including ganciclovir (Cytovene), valganciclovir (Valcyte), foscarnet (Foscavir), and cidofovir (Vistide). The most commonly used treatment today is oral valganciclovir because of its convenience and excellent absorption.
Systemic treatment is preferred because CMV often affects more than just the eyes. Treating the whole body helps control the virus in other organs as well. Therapy typically begins with a higher induction dose for two to three weeks, or until the retinitis stabilizes. After that, the dose is reduced to a lower maintenance level.
In some cases, a retina specialist may administer antiviral medication directly into the eye through an intravitreal injection (an injection into the gel-filled space inside the eye). Ganciclovir and foscarnet can be delivered this way. Intravitreal injections are often used early in treatment alongside systemic therapy. This achieves faster control of the infection, especially when it threatens the macula or optic nerve.
Another option previously available is fomivirsen (Vitravene), an intravitreal injection. The ganciclovir implant (Vitrasert) is a small device surgically placed inside the eye that slowly releases medication over several months. Treatment decisions are individualized based on the location and severity of the retinitis and the patient's overall immune status.
For patients with HIV, the most important long-term strategy is restoring the immune system through HAART. The introduction of HAART has reduced the incidence of CMV retinitis by 55 to 99 percent (AAO EyeWiki). It has also cut the odds of disease progression by 50 percent (AAO EyeWiki). When CD4+ T-cell counts rise above a sustained level, the risk of CMV reactivation drops significantly. Maintenance antiviral therapy may eventually be discontinued under close medical supervision.
A promising area of research is adoptive cell transfer. This involves infusing patients with CMV-specific cytotoxic T lymphocytes, a type of immune cell trained to fight CMV. In a small study, this approach led to resolution of CMV retinitis in 9 out of 10 treated eyes over an average follow-up of 30 months. Mean best-corrected visual acuity at the final follow-up visit was 20/78. This immunotherapy approach may be especially valuable for transplant patients who must remain on immunosuppression.
What to Expect
Treatment for CMV retinitis requires close monitoring by a retina specialist. During the induction phase, which lasts two to three weeks, patients take higher doses of antiviral medication. Eye examinations are performed frequently to check whether the borders of the infection are stabilizing. If intravitreal injections are used, patients may receive one or more injections during this initial period.
Most antiviral medications can cause side effects. Ganciclovir and valganciclovir can lower blood cell counts, requiring regular blood tests. Foscarnet can affect kidney function and cause mineral imbalances in the blood. A retina specialist and the patient's primary medical team will work together to monitor for these effects.
The long-term outlook for CMV retinitis depends heavily on immune recovery. Before HAART, one in three eyes with CMV retinitis progressed to retinal detachment. With HAART therapy, that figure has improved to about one in eight eyes (AAO). Retinal detachment can occur because the areas of retina destroyed by CMV become thin and fragile.
Even with successful treatment, vision may not return to what it was before the infection. The virus destroys retinal tissue, and vision lost before treatment begins is typically not recoverable. This is why early detection and prompt treatment are so important.
After the infection stabilizes, patients typically continue on a lower maintenance dose of antiviral medication. Regular follow-up appointments with a retina specialist are essential to watch for signs of reactivation. If the immune system recovers sufficiently, maintenance therapy may be carefully stopped. Ongoing eye examinations remain important because the virus can reactivate if immune function declines again.
Living With CMV Retinitis
The most important step in preventing CMV retinitis from worsening or returning is maintaining a strong immune system. For people with HIV, this means consistent adherence to antiretroviral therapy. For transplant recipients, it means working closely with a transplant team to balance immunosuppression with infection risk. Regular medical checkups and blood tests to monitor immune function are critical parts of ongoing care.
Some patients with CMV retinitis experience lasting vision changes, especially if the macula or optic nerve was affected. Low vision rehabilitation services can help patients make the most of their remaining vision. These services may include training with magnification devices, strategies for daily activities, and adjustments to lighting and contrast.
Living with a condition that threatens vision can be emotionally challenging, especially when combined with an underlying immune condition. Patients may benefit from counseling and support groups for people with visual impairment. Connecting with organizations that offer resources for people living with HIV or other immune disorders can also help. A retina specialist can help connect patients with appropriate support services.
When to See a Retina Specialist
Anyone with a severely weakened immune system should have regular eye examinations by a retina specialist, even without vision complaints. This is especially important for patients with CD4 counts below 50 cells per microliter. It also applies to those who have recently started or changed immunosuppressive therapy and transplant recipients in the first year after surgery.
Seek immediate care from a retina specialist or go to the emergency room if you experience a sudden increase in floaters, flashes of light, a shadow or curtain moving across your vision, or sudden loss of vision in one eye. Early treatment of CMV retinitis can prevent significant and irreversible vision loss. Do not wait for symptoms to improve on their own.
Questions and Answers
Yes, CMV retinitis can reactivate, particularly if the immune system weakens again. The cytomegalovirus remains dormant in the body even after successful treatment. Patients who stop maintenance antiviral therapy or whose immune function declines are at risk for recurrence. Ongoing monitoring with a retina specialist is essential to catch any reactivation early.
CMV retinitis itself is not contagious in the way a cold or flu spreads. However, cytomegalovirus is a very common virus that can be transmitted through bodily fluids such as saliva, blood, and breast milk. Most people who contract CMV do not develop retinitis because a healthy immune system keeps the virus inactive. Only people with severely weakened immune systems are at risk for the retinitis complication.
Retinal tissue destroyed by CMV retinitis does not regenerate. Vision that is lost before treatment begins is typically not recoverable. This is why early detection through regular screening is so important for high-risk individuals. Treatment can stop the infection from spreading further and preserve remaining vision, but it cannot restore areas of retina that have been destroyed.
The initial induction phase of treatment typically lasts two to three weeks. After that, patients usually continue a lower-dose maintenance regimen. The total duration of treatment depends on the patient's immune status. For people with HIV who achieve strong immune recovery through HAART, maintenance therapy may eventually be stopped under careful medical supervision. Transplant recipients and others on long-term immunosuppression may need prolonged or indefinite monitoring.
The most effective prevention for people with HIV is consistent use of antiretroviral therapy to keep CD4+ T-cell counts well above 50 cells per microliter. For transplant recipients, antiviral prophylaxis may be prescribed during the period of highest risk. Regular screening eye examinations are a critical preventive measure for all high-risk patients. Early detection can occur before significant vision damage develops.